ENSYSCE BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$430.44 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2024-03-15
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-12-31 was -$4.08K.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-09-30 was -$17.22K.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-06-30 was -$43.62K.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-03-31 was -$365.51K.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2023 was -$430.44K.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2022 was -$12.49M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$4.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$21.31K derived: sum of 2 quarters · filed 2024-03-15 | -$64.93K derived: sum of 3 quarters · filed 2024-03-15 | -$430.44K 10-K · filed 2024-03-15 |
| 2023-09-30 | -$17.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$60.84K derived: sum of 2 quarters · filed 2023-11-09 | -$426.35K 10-Q · filed 2023-11-09 | -$4.73M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | -$43.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$409.13K 10-Q · filed 2023-08-11 | -$4.71M derived: sum of 3 quarters · filed 2023-08-11 | -$7.28M derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | -$365.51K 10-Q · filed 2023-05-15 | -$4.67M derived: sum of 2 quarters · filed 2023-05-15 | -$7.23M derived: sum of 3 quarters · filed 2023-05-15 | |
| 2022-12-31 | -$4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$6.87M derived: sum of 2 quarters · filed 2023-03-30 | -$12.49M 10-K · filed 2023-03-30 | |
| 2022-09-30 | -$2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$8.19M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | -$5.62M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |